|
시장보고서
상품코드
2018297
다사티닙 시장 규모, 점유율, 동향 분석 보고서 : 약물 유형별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)Dasatinib Market Size, Share & Trends Analysis Report By Drug Type, (Branded, Generic), By Indication (Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL)), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
다사티닙 시장 요약
세계의 다사티닙 시장 규모는 2025년에 55억 9,000만 달러로 추정되며, 2033년까지 75억 7,000만 달러에 달할 것으로 예측되며, 2026년부터 2033년까지 CAGR 4.27%로 성장할 것으로 전망됩니다.
세계 다사티닙 시장은 혈액 악성 종양, 특히 만성 골수성 백혈병과 필라델피아 염색체 양성 급성 림프구성 백혈병의 유병률 증가로 인해 확대되고 있습니다.
표적 암 치료에 대한 인식이 높아짐에 따라 선진국과 신흥국에서 진단 정확도가 향상되고 조기 치료가 시작되고 있습니다. 의사들은 지속적인 질병 조절을 위해 티로신 키나아제 억제제를 선호하고 있으며, 이는 장기적인 수요를 뒷받침하고 있습니다. 생존기간의 연장으로 약물의 누적 사용량이 증가하여 수익 전망이 밝아지고 있습니다. 예를 들어, 2025년 11월, OnLive는 FDA가 20mg, 50mg, 70mg, 80mg, 100mg, 140mg 등 6가지 용량의 다사티닙 복제약에 대한 간소화된 신약허가신청(ANDA)을 승인했다고 보도했습니다. 2006년 최초 승인을 받았으며, 2019년 1월 78명의 소아 환자를 대상으로 한 임상 2상 시험 결과를 바탕으로 적응증 확대가 이루어졌습니다. 이 시험에서 3년 무사건 생존율은 64.1%(95% 신뢰구간 : 52.4%-74.7%), 도입요법 시 골수모세포가 5% 미만인 비율은 96%, 강화요법 시에는 97%였으며, 81명의 환자 중 치명적인 이상반응은 4%, 치료 중단은 10%였습니다.
정밀의료와 분자진단의 발전으로 바이오마커에 기반한 치료법 선택이 강화되고, 다사티닙과 같은 표적 치료제의 채택이 가속화되고 있습니다. 내성 또는 불내성 만성 골수성 백혈병에 대한 임상적 증거는 의사들의 신뢰를 높이고 2세대 티로신키나아제 억제제에 대한 가이드라인의 권고를 뒷받침하고 있습니다. 예를 들어, 2026년 1월 Cancer Reports는 2002년부터 2025년까지 저용량 다사티닙(1일 50mg)으로 치료받은 성인 53명(중앙값 50세)을 대상으로 한 후향적 분석 결과를 발표하였습니다. 분자학적 반응 결과, 41.5%가 MR4.5, 20.8%가 MR4.0, 15.1%가 심부반응을 동반하지 않는 주요 분자학적 반응을 달성했습니다. 티로신 키나아제 도메인의 돌연변이는 32.1%에서 발견되었고, 임상적으로 심각한 부작용은 49.1%에서 발생하였습니다. 또한, 22.6%는 불충분한 반응으로, 7.5%는 내약성 불량으로 약제 변경이 필요했습니다. 기준선에서 BCR-ABL1이 100% 이상, T315I 돌연변이, ELTS 위험이 높을수록 예후가 좋지 않은 예측인자임을 알 수 있었습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 다사티닙 시장 : 변수, 동향, 범위
제4장 다사티닙 시장 : 약물 유형별 비즈니스 분석
제5장 다사티닙 시장 : 적응증별 비즈니스 분석
제6장 다사티닙 시장 : 유통 채널별 비즈니스 분석
제7장 다사티닙 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSM 26.05.13Dasatinib Market Summary
The global dasatinib market size was estimated at USD 5.59 billion in 2025 and is projected to reach USD 7.57 billion by 2033, growing at a CAGR of 4.27% from 2026 to 2033. The global dasatinib market is expanding due to the rising prevalence of hematologic malignancies, particularly chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.
Increasing awareness of targeted oncology therapies has improved diagnosis and early treatment initiation across developed and emerging regions. Physicians prefer tyrosine kinase inhibitors for sustained disease control, supporting long term demand. Longer survival has increased cumulative drug utilization, strengthening revenue visibility. For instance, November 2025, OncLive reported FDA approval of a generic dasatinib abbreviated new drug application in six strengths, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. Initial clearance occurred in 2006, with expansion in January 2019 based on a phase 2 trial in 78 pediatric patients showing 64.1 percent 3 year event free survival, 95 percent confidence interval 52.4 percent to 74.7 percent, 96 percent below 5 percent marrow blasts at induction, 97 percent at consolidation, 4 percent fatal adverse effects among 81 patients, and 10 percent discontinuation.
Advancements in precision medicine and molecular diagnostics have strengthened biomarker driven therapy selection, accelerating adoption of targeted treatments such as dasatinib. Clinical evidence in resistant or intolerant chronic myeloid leukemia has reinforced physician confidence and supported guideline recommendations for second generation tyrosine kinase inhibitors. For instance, January 2026, Cancer Reports published a retrospective analysis of 53 adults treated with low dose dasatinib 50 mg daily between 2002 and 2025, with a median age of 50 years. Molecular response outcomes included 41.5 percent achieving MR4.5, 20.8 percent MR4.0, and 15.1 percent major molecular response without deep response. Tyrosine kinase domain mutations were present in 32.1 percent, clinically significant adverse events in 49.1 percent, 22.6 percent required switching for inadequate response, and 7.5 percent for intolerance. Baseline BCR ABL1 greater than or equal to 100 percent, T315I mutation, and high ELTS risk predicted poorer outcomes.
Global Dasatinib Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dasatinib market report based on drug type, indication, distribution channel, and region:
- Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
- Branded
- Generic
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphoblastic Leukemia (ALL)
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Oncology Pharmacies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Type
- 1.2.2. Indication
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Dasatinib Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Dasatinib Market: Drug Type Business Analysis
- 4.1. Drug Type Market Share, 2025 & 2033
- 4.2. Drug Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
- 4.4. Branded
- 4.4.1. Branded Market, 2021 - 2033 (USD Million)
- 4.5. Generic
- 4.5.1. Generic Market, 2021 - 2033 (USD Million)
Chapter 5. Dasatinib Market: Indication Business Analysis
- 5.1. Indication Market Share, 2025 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 5.4. Chronic Myeloid Leukemia (CML)
- 5.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
- 5.5. Acute Lymphoblastic Leukemia (ALL)
- 5.5.1. Acute Lymphoblastic Leukemia (ALL) Market, 2021 - 2033 (USD Million)
Chapter 6. Dasatinib Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2025 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
- 6.7. Specialty Oncology Pharmacies
- 6.7.1. Specialty Oncology Pharmacies Market, 2021 - 2033 (USD Million)
Chapter 7. Dasatinib Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Dasatinib Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Target Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Target Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Target Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Target Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Target Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Bristol-Myers Squibb Company
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Teva Pharmaceutical Industries Ltd.
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Sandoz Group AG
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Sun Pharmaceutical Industries Limited
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Hetero Drugs Limited
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Aurobindo Pharma Limited
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Dr. Reddy's Laboratories Limited
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Intas Pharmaceuticals Ltd.
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Cipla Limited
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Lupin Limited
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.1. Bristol-Myers Squibb Company
